logo

For the Inventor, By the Inventor

New York, NY, United States of America

Receptos, Inc.


USPTO Granted Patents = 25

% Expired Patents = 12.0



Trademarks = 2

Forward Citations = 72

Loading Chart...
Loading Chart...

49 inventors (with patents filed for the assignee):

goldMedal Junko Tamiya (12 out of 26 patents)

silverMedal Liming Huang (11 out of 39 patents)

bronzeMedal Manisha Moorjani (10 out of 25 patents)

4.  Marcus F Boehm (10 out of 64 patents)

5.  Esther Martinborough (10 out of 77 patents)

6.  Adam Richard Yeager (10 out of 32 patents)

7.  Enugurthi Brahmachary (8 out of 18 patents)

8.  Thomas Fowler (7 out of 14 patents)

9.  Yanfeng Zhang (6 out of 59 patents)

10.  Minhua Chen (6 out of 57 patents)

11.  Chaohui Yang (6 out of 16 patents)

12.  Andrew Richard Novak (6 out of 20 patents)

13.  Xiaoting Zhai (6 out of 9 patents)

14.  Kaiqiang Yan (6 out of 8 patents)

15.  Premji Meghani (6 out of 40 patents)


Core Competencies:
Sphingosine 1 Phosphate
GLP-1 Receptor
Atopic Dermatitis
Ozanimod
Lupus
Neuroprotection
Chiral Synthesis
Crystalline Forms
CXCR3 Receptor
Selective Modulators

25 patents:

1. 12428386 - Sphingosine 1 phosphate receptor modulators (2025-09-30),
2. 12421199 - Sphingosine 1 phosphate receptor modulators (2025-09-23),
3. 12364686 - Sphingosine 1 phosphate receptor modulators (2025-07-22),
4. 11964005 - Methods of treating atopic dermatitis (2024-04-23),
5. 11897848 - Crystalline forms of ozanimod and processes for preparation thereof (2024-02-13),
6. 11680050 - Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof (2023-06-20),
7. 11530205 - GLP-1 receptor modulators (2022-12-20),
8. 11278526 - Compounds and methods for treating lupus (2022-03-22),
9. 11207301 - Sphingosine 1 phosphate receptor agonists for neuroprotection (2021-12-28),
10. 11117876 - Crystalline form of ozanimod hydrochloride, and processes for preparation thereof (2021-09-14),
11. 11111223 - Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof (2021-09-07),
12. 11066395 - Dimethylaminoethanol salt of a GLP-1 receptor modulator (2021-07-20),
13. 11040954 - CXCR3 receptor agonists (2021-06-22),
14. 11028060 - Crystalline forms of ozanimod and processes for preparation thereof (2021-06-08),
15. 10882830 - Crystal form of ozanimod hydrochloride and processes for preparation therefor (2021-01-05),
Company Overview
Receptos, Inc. is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The organization focuses on advancing its proprietary drug candidates through rigorous research and clinical trials, aiming to address unmet medical needs in areas such as multiple sclerosis and ulcerative colitis. With a commitment to scientific excellence, Receptos leverages cutting-edge technology and a deep understanding of disease mechanisms to drive its therapeutic innovations.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

25 Patents

#339 in New York, NY

#788 in New York

#13,364 in US

#25,710 in the World

New York, NY (US)
New York, NY, United States of America

Receptos, Inc.

Forward Citations = 72

49 inventors:

goldMedal Junko Tamiya (12 out of 26 patents)

silverMedal Liming Huang (11 out of 39 patents)

bronzeMedal Manisha Moorjani (10 out of 25 patents)

4.  Marcus F Boehm (10 out of 64 patents)

5.  Esther Martinborough (10 out of 77 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Receptos, Inc.. Retrieved from https://idiyas.com/company/receptos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…